Document:

Exhibit
      10.83

    

    NEITHER
      THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE
      BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
      COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
      THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
      MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
      STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
      OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
      SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
      EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR REASONABLY ACCEPTABLE
      TO THE COMPANY TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
      ACCEPTABLE TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
      A
      BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH
      A
      FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a)
      UNDER THE SECURITIES ACT. 

     

    COMMON
      STOCK PURCHASE WARRANT

    

    To
      Purchase [  ]
      Shares
      of Common Stock of

    

    TASKER
      PRODUCTS CORP.

    

    
      	No. W- [  ]	 	
              __________,
                2007

            

    

              

     

    THIS
      COMMON STOCK PURCHASE WARRANT (the “Warrant”)
      CERTIFIES that, for value received, INDIGO SECURITIES, LLC (the “Holder”),
      is
      entitled, upon the terms and subject to the limitations on exercise and the
      conditions hereinafter set forth, at any time on or after the date of this
      Warrant and on or prior to the seventh (7th)
      anniversary of the date of this Warrant (the “Termination
      Date”)
      but
      not thereafter, to subscribe for and purchase from Tasker Products Corp., a
      Nevada corporation (the “Company”),
      up to
      [ ]
      shares
      (the “Warrant
      Shares”)
      of the
      Common Stock, par value $0.001 per share, of the Company (the “Common
      Stock”).
      The
      purchase price of one share of Common Stock (the “Exercise
      Price”)
      under
      this Warrant shall be US [$0.09]. The Exercise Price and the number of Warrant
      Shares for which the Warrant is exercisable shall be subject to adjustment
      as
      provided herein. Capitalized terms used and not otherwise defined herein shall
      have the meanings set forth in that certain Subscription Agreement (the
“Subscription
      Agreement”),
      among
      the Company and the Purchaser parties signatory thereto (such date, the
“Closing
      Date”).
      

    

    1.
       Title
      to Warrant.
      Prior
      to the Termination Date and subject to compliance with applicable laws,
      including transfer restrictions imposed by applicable securities laws, and
      Section 7 of this Warrant, this Warrant and all rights hereunder are
      transferable, in whole or in part, at the office or agency of the Company by
      the
      Holder in person or by duly authorized attorney, upon surrender of this Warrant
      together with the Assignment Form annexed hereto properly endorsed. The
      transferee shall sign an investment letter in form and substance reasonably
      satisfactory to the Company. 

    

    2 Authorization
      of Shares.
      The
      Company covenants that all Warrant Shares, which may be issued upon the exercise
      of the purchase rights represented by this Warrant in accordance with the terms
      of this Warrant, including the payment of the exercise price for such Warrant
      Shares, will, upon exercise of the purchase rights represented by this Warrant,
      be duly authorized, validly issued, fully paid and nonassessable and free from
      all taxes, liens and charges in respect of the issue thereof (other than taxes
      in respect of any transfer occurring contemporaneously with such issue).

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    3.
       Exercise
      of Warrant.
      

    

    (a)
       Exercise
      of the purchase rights represented by this Warrant may be made at any time
      or
      times on or after the date hereof but on or before the Termination Date by
      

    

    (i) delivery
      to the Company of a duly executed Notice of Exercise Form annexed hereto (or
      such other office or agency of the Company as it may designate by notice in
      writing to the registered Holder at the address of such Holder appearing on
      the
      books of the Company) and surrender of this Warrant, together with payment
      of
      the aggregate Exercise Price of the shares thereby purchased by wire transfer
      or
      cashier’s check drawn on a United States bank in immediately available funds.
      Certificates for shares purchased hereunder shall be delivered to the Holder
      within 5 Trading Days from the delivery to the Company of the Notice of Exercise
      Form, surrender of this Warrant and payment of the aggregate Exercise Price
      as
      set forth above (“Warrant
      Share Delivery Date”).
      This
      Warrant shall be deemed to have been exercised on the later of the date the
      Notice of Exercise is delivered to the Company and the date the Exercise Price
      is received by the Company. The Warrant Shares shall be deemed to have been
      issued, and Holder or any other person so designated to be named therein shall
      be deemed to have become a holder of record of such shares for all purposes,
      as
      of the date the Warrant has been exercised by payment to the Company of the
      Exercise Price and all taxes required to be paid by the Holder, if any, pursuant
      to Section 5 prior to the issuance of such shares, have been paid. If the
      Company fails to deliver to the Holder a certificate or certificates
      representing the Warrant Shares pursuant to this Section 3(a) by the end of
      business (New York, New York time) on the fifth Trading Day following
      the Warrant Share Delivery Date, then the Holder will have the right to rescind
      such exercise. Nothing herein shall limit a Holder's right to pursue any other
      remedies available to it hereunder, at law or in equity including, without
      limitation, a decree of specific performance and/or injunctive relief with
      respect to the Company's failure to timely deliver certificates representing
      shares of Common Stock upon exercise of the Warrant as required pursuant to
      the
      terms hereof. 

    

    (ii) by
      the
      exchange of this Warrant in whole or in part (with the Cashless Exercise
      subscription form in the form annexed hereto duly executed) (a “Cashless
      Exercise”)
      at the
      address of the Company set forth herein. Such presentation and exchange shall
      be
      deemed a waiver of the Holder's obligation to pay the Exercise Price or, in
      the
      case of a partial exercise of this Warrant, of the portion of the Exercise
      Price
      that would otherwise be payable in connection with such partial exercise. Upon
      presentment of this Warrant in connection with a Cashless Exercise, the number
      of Warrant Shares subject to this Warrant shall be reduced by the number of
      Warrant Shares specified on the Cashless Exercise subscription form, and in
      exchange for such reduction the Holder shall receive the number of Warrant
      Shares, as the case may be, specified on the Cashless Exercise subscription
      form
      (up to the total number of Warrant Shares which are subject to this Warrant)
      multiplied by a fraction, the numerator of which shall be the difference between
      the then current market price per share of the Common Stock and the Exercise
      Price per share, and the denominator of which shall be the then current market
      price per share of Common Stock. For purposes of any computation under this
      Section 3(a), the then current market price shall be the closing price on the
      trading day immediately prior to the execution of the Cashless Exercise
      subscription form by Holder.

    

    (b)
       If
      this
      Warrant shall have been exercised in part, the Company shall, at the time of
      delivery of the certificate or certificates representing Warrant Shares, deliver
      to Holder a new Warrant evidencing the rights of Holder to purchase the
      unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
      in all other respects be identical with this Warrant. 

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4.
       No
      Fractional Shares or Scrip.
       No
      fractional shares or scrip representing fractional shares shall be issued upon
      the exercise of this Warrant. As to any fraction of a share which Holder would
      otherwise be entitled to purchase upon such exercise, the Company shall pay
      a
      cash adjustment in respect of such final fraction in an amount equal to such
      fraction multiplied by the Exercise Price.

     

    5.
       Charges,
      Taxes and Expenses.
       Issuance
      of certificates for Warrant Shares shall be made without charge to the Holder
      for any issue or transfer tax or other incidental expense in respect of the
      issuance of such certificate, all of which taxes and expenses shall be paid
      by
      the Company, and such certificates shall be issued in the name of the Holder
      or
      in such name or names as may be directed by the Holder; provided, however,
      that
      in the event certificates for Warrant Shares are to be issued in a name other
      than the name of the Holder, this Warrant when surrendered for exercise shall
      be
      accompanied by the Assignment Form attached hereto duly executed by the Holder;
      and the Company may require, as a condition thereto, the payment of a sum
      sufficient to reimburse it for any transfer tax incidental thereto.

    

    6.
       Closing
      of Books.
       The
      Company will not close its stockholder books or records in any manner which
      prevents the timely exercise of this Warrant, pursuant to the terms hereof.
      

    

    7.
       Transfer,
      Division and Combination.
      

    

    (a)
       Subject
      to compliance with any applicable securities laws and the conditions set forth
      in Sections 1 and 7(e) hereof and to the provisions of Section 4.1 of the
      Subscription Agreement, this Warrant and all rights hereunder are transferable,
      in whole or in part, upon surrender of this Warrant at the principal office
      of
      the Company, together with a written assignment of this Warrant substantially
      in
      the form attached hereto duly executed by the Holder or its agent or attorney
      and funds sufficient to pay any transfer taxes payable upon the making of such
      transfer. Upon such surrender and, if required, such payment, the Company shall
      execute and deliver a new Warrant or Warrants in the name of the assignee or
      assignees and in the denomination or denominations specified in such instrument
      of assignment, and shall issue to the assignor a new Warrant evidencing the
      portion of this Warrant not so assigned, and this Warrant shall promptly be
      cancelled. A Warrant, if properly assigned, may be exercised by a new holder
      for
      the purchase of Warrant Shares without having a new Warrant issued.
      Notwithstanding the foregoing, the Holder will not voluntarily and knowingly
      assign or transfer this Warrant or the Warrant Shares to any direct competitor
      of the Company without the Company’s prior written consent.

    

    (b)
       This
      Warrant may be divided or combined with other Warrants upon presentation hereof
      at the aforesaid office of the Company, together with a written notice
      specifying the names and denominations in which new Warrants are to be issued,
      signed by the Holder or its agent or attorney. Subject to compliance with
      Section 7(a), as to any transfer which may be involved in such division or
      combination, the Company shall execute and deliver a new Warrant or Warrants
      in
      exchange for the Warrant or Warrants to be divided or combined in accordance
      with such notice. 

    

    (c)
       The
      Company shall prepare, issue and deliver at its own expense (other than transfer
      taxes) the new Warrant or Warrants under this Section 7. 

    

    (d)
       The
      Company agrees to maintain, at its aforesaid office, books for the registration
      and the registration of transfer of the Warrants. 

    

    (e)
       The
      Company may require, as a condition of allowing such transfer (i) that the
      Holder or transferee of this Warrant, as the case may be, furnish to the Company
      a written opinion of counsel reasonably acceptable to the Company (which opinion
      shall be in form, substance and scope customary for opinions of counsel in
      comparable transactions) to the effect that such transfer may be made without
      registration under the Securities Act and under applicable state securities
      or
      blue sky laws, (ii) that the holder or transferee execute and deliver to the
      Company an investment letter in form and substance acceptable to the Company
      and
      (iii) that the transferee be an “accredited investor” as defined in Rule 501(a)
      promulgated under the Securities Act or a qualified institutional buyer as
      defined in Rule 144A(a) under the Securities Act.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    8.
       No
      Rights as Shareholder until Exercise.
       This
      Warrant does not entitle the Holder to any voting rights or other rights as
      a
      shareholder of the Company prior to the exercise hereof. Upon the surrender
      of
      this Warrant and the payment of the aggregate Exercise Price, the Warrant Shares
      so purchased shall be and be deemed to be issued to such Holder as the record
      owner of such shares as of the close of business on the later of the date of
      such surrender or payment. 

    

    9.
       Loss,
      Theft, Destruction or Mutilation of Warrant.
       The
      Company covenants that upon receipt by the Company of evidence reasonably
      satisfactory to it of the loss, theft, destruction or mutilation of this Warrant
      or any stock certificate relating to the Warrant Shares, and in case of loss,
      theft or destruction, of indemnity or security reasonably satisfactory to it
      (which, in the case of the Warrant, shall not include the posting of any bond),
      and upon surrender and cancellation of such Warrant or stock certificate, if
      mutilated, the Company will make and deliver a new Warrant or stock certificate
      of like tenor and dated as of such cancellation, in lieu of such Warrant or
      stock certificate. 

    

    10.
       Saturdays,
      Sundays, Holidays, etc.
       If
      the
      last or appointed day for the taking of any action or the expiration of any
      right required or granted herein shall be a Saturday, Sunday or a legal holiday,
      then such action may be taken or such right may be exercised on the next
      succeeding day not a Saturday, Sunday or legal holiday. 

    

    11.
       Adjustments
      of Exercise Price and Number of Warrant Shares.
       (a)
      The
      number and kind of securities purchasable upon the exercise of this Warrant
      and
      the Exercise Price shall be subject to adjustment from time to time upon the
      happening of any of the following: in case the Company shall (i) pay a dividend
      in shares of Common Stock or make a distribution in shares of Common Stock
      to
      holders of its outstanding Common Stock; (ii) subdivide its outstanding shares
      of Common Stock into a greater number of shares; (iii) combine its outstanding
      shares of Common Stock into a smaller number of shares of Common Stock; or
      (iv)
      issue any shares of its capital stock in a reclassification of the Common Stock,
      then the number of Warrant Shares purchasable upon exercise of this Warrant
      immediately prior thereto shall be adjusted so that the Holder shall be entitled
      to receive the kind and number of Warrant Shares or other securities of the
      Company which it would have owned or have been entitled to receive had such
      Warrant been exercised in advance thereof. Upon each such adjustment of the
      kind
      and number of Warrant Shares or other securities of the Company which are
      purchasable hereunder, the Holder shall thereafter be entitled to purchase
      the
      number of Warrant Shares or other securities resulting from such adjustment
      at
      an Exercise Price per Warrant Share or other security obtained by multiplying
      the Exercise Price in effect immediately prior to such adjustment by the number
      of Warrant Shares purchasable pursuant hereto immediately prior to such
      adjustment and dividing by the number of Warrant Shares or other securities
      of
      the Company that are purchasable pursuant hereto immediately after such
      adjustment. An adjustment made pursuant to this paragraph shall become effective
      immediately after the effective date of such event retroactive to the record
      date, if any, for such event. 

    

       (b) In
      the
      event that on or subsequent to the Closing Date, the Company issues or sells
      any
      Common Stock, any convertible securities, or any warrants or other rights to
      subscribe for or to purchase or any options for the purchase of its Common
      Stock
      or any such convertible securities (other than (i) shares which are issued
      pursuant to the Securities, (ii)
      shares of Common Stock or options to purchase such shares issued to employees,
      consultants, officers or directors in accordance with stock plans approved
      by
      the Company’s Board of Directors, and shares of Common Stock issuable under
      options or warrants that are outstanding as of the date hereof, or (iii) shares
      of Common Stock issued pursuant to a stock dividend, split or other similar
      transaction) at
      an
      effective price per share which is less than the then applicable Exercise Price
      (such effective price per share, the “Adjusted
      Exercise Price”),
      then
      the Exercise Price in effect immediately prior to such issue or sale shall
      be
      reduced effective concurrently with such issue or sale to an amount equal to
      the
      Adjusted Exercise Price. 

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    12.
       Reorganization,
      Reclassification, Merger, Consolidation or Disposition of Assets.
      In case
      the Company shall reorganize its capital, reclassify its capital stock,
      consolidate or merge with or into another corporation (where the Company is
      not
      the surviving corporation or where there is a change in or distribution with
      respect to the Common Stock of the Company), or sell, transfer or otherwise
      dispose of its property, assets or business to another corporation and, pursuant
      to the terms of such reorganization, reclassification, merger, consolidation
      or
      disposition of assets, shares of common stock of the successor or acquiring
      corporation, or any cash, shares of stock or other securities or property of
      any
      nature whatsoever (including warrants or other subscription or purchase rights)
      in addition to or in lieu of common stock of the successor or acquiring
      corporation (“Other
      Property”),
      are
      to be received by or distributed to the holders of Common Stock of the Company,
      then, from and after the consummation of such transaction or event, the Holder
      shall have the right thereafter to receive, instead of the Warrant Shares,
      at
      the option of the Holder, (a) upon exercise of this Warrant, the number of
      shares of Common Stock of the successor or acquiring corporation or of the
      Company, if it is the surviving corporation, and Other Property receivable
      upon
      or as a result of such reorganization, reclassification, merger, consolidation
      or disposition of assets by a Holder of the number of shares of Common Stock
      for
      which this Warrant is exercisable immediately prior to such event or (b) if
      the
      Company is acquired in an all cash transaction, cash equal to the value of
      this
      Warrant as determined in accordance with the Black-Scholes option pricing
      formula. For purposes of this Section 12, “common stock of the successor or
      acquiring corporation” shall include stock of such corporation of any class
      which is not preferred as to dividends or assets over any other class of stock
      of such corporation and which is not subject to redemption and shall also
      include any evidences of indebtedness, shares of stock or other securities
      which
      are convertible into or exchangeable for any such stock, either immediately
      or
      upon the arrival of a specified date or the happening of a specified event
      and
      any warrants or other rights to subscribe for or purchase any such stock. The
      foregoing provisions of this Section 12 shall similarly apply to successive
      reorganizations, reclassifications, mergers, consolidations or disposition
      of
      assets. 

    

    13.
       Notice
      of Adjustment.
       Whenever
      the number of Warrant Shares or number or kind of securities or other property
      purchasable upon the exercise of this Warrant or the Exercise Price is adjusted,
      as herein provided, the Company shall give notice thereof to the Holder, which
      notice shall state the number of Warrant Shares (and other securities or
      property) purchasable upon the exercise of this Warrant and the Exercise Price
      of such Warrant Shares (and other securities or property) after such adjustment,
      setting forth a brief statement of the facts requiring such adjustment and
      setting forth the computation by which such adjustment was made. 

    

    14.
       Notice
      of Corporate Action.
       If
      at any
      time:

     

    (a)
       the
      Company shall take a record of the holders of its Common Stock for the purpose
      of entitling them to receive a dividend or other distribution, or 

    

    (b)
       there
      shall be any capital reorganization of the Company, any reclassification or
      recapitalization of the capital stock of the Company or any consolidation or
      merger of the Company with, or any sale, transfer or other disposition of all
      or
      substantially all the property, assets or business of the Company to, another
      corporation or, 

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (c)
       there
      shall be a voluntary or involuntary dissolution, liquidation or winding up
      of
      the Company; then, in any one or more of such cases, the Company shall give
      to
      Holder (i) prior written notice of the date on which a record date shall be
      selected for such dividend or distribution or for determining rights to vote
      in
      respect of any such reorganization, reclassification, merger, consolidation,
      sale, transfer, disposition, liquidation or winding up, and (ii) in the case
      of
      any such reorganization, reclassification, merger, consolidation, sale,
      transfer, disposition, dissolution, liquidation or winding up, prior written
      notice of the date when the same shall take place. Such notice in accordance
      with the foregoing clause also shall specify (i) the date on which the holders
      of Common Stock shall be entitled to any such dividend or distribution, and
      the
      amount and character thereof, and (ii) the date on which any such
      reorganization, reclassification, merger, consolidation, sale, transfer,
      disposition, dissolution, liquidation or winding up is to take place and the
      time, if any such time is to be fixed, as of which the holders of Common Stock
      shall be entitled to exchange their Warrant Shares for securities or other
      property deliverable upon such disposition, dissolution, liquidation or winding
      up. Each such written notice shall be sufficiently given if addressed to Holder
      at the last address of Holder appearing on the books of the Company and
      delivered in accordance with Section 16(d). 

    

    15.
       Authorized
      Shares.
       The
      Company covenants that during the period the Warrant is outstanding, it will
      reserve from its authorized and unissued Common Stock a sufficient number of
      shares to provide for the issuance of the Warrant Shares upon the exercise
      of
      any purchase rights under this Warrant. The Company further covenants that
      its
      issuance of this Warrant shall constitute full authority to its officers who
      are
      charged with the duty of executing stock certificates to execute and issue
      the
      necessary certificates for the Warrant Shares upon the exercise of the purchase
      rights under this Warrant. The Company will take all such reasonable action
      as
      may be necessary to assure that such Warrant Shares may be issued as provided
      herein without violation of any applicable law or regulation, or of any
      requirements of the Trading Market upon which the Common Stock may be listed.
      

    

    Except
      and to the extent as waived or consented to by the Holder, the Company shall
      not
      by any action, including, without limitation, amending its certificate of
      incorporation or through any reorganization, transfer of assets, consolidation,
      merger, dissolution, issue or sale of securities or any other voluntary action,
      avoid or seek to avoid the observance or performance of any of the terms of
      this
      Warrant, but will at all times in good faith assist in the carrying out of
      all
      such terms and in the taking of all such actions as may be necessary or
      appropriate to protect the rights of Holder as set forth in this Warrant against
      impairment. Without limiting the generality of the foregoing, the Company will
      (a) not increase the par value of any Warrant Shares above the amount payable
      therefore upon such exercise immediately prior to such increase in par value,
      (b) take all such action as may be necessary or appropriate in order that the
      Company may validly and legally issue fully paid and nonassessable Warrant
      Shares upon the exercise of this Warrant, and (c) use commercially reasonable
      efforts to obtain all such authorizations, exemptions or consents from any
      public regulatory body having jurisdiction thereof as may be necessary to enable
      the Company to perform its obligations under this Warrant. 

    

    Before
      taking any action which would result in an adjustment in the number of Warrant
      Shares for which this Warrant is exercisable or in the Exercise Price, the
      Company shall obtain all such authorizations or exemptions thereof, or consents
      thereto, as may be necessary from any public regulatory body or bodies having
      jurisdiction thereof. 

    

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    16.
       Miscellaneous.
      

    

    (a)
       Jurisdiction.
       All
      questions concerning the construction, validity, enforcement and interpretation
      of this Warrant shall be determined in accordance with the provisions of the
      Subscription Agreement relating to the same. 

    

    (b)
       Restrictions.
       The
      Holder acknowledges that the Warrant Shares acquired upon the exercise of this
      Warrant, if not registered for resale, will have restrictions upon resale
      imposed by state and federal securities laws. 

    

    (c)
       Nonwaiver
      and Expenses.
       No
      course
      of dealing or any delay or failure to exercise any right hereunder on the part
      of Holder shall operate as a waiver of such right or otherwise prejudice
      Holder’s rights, powers or remedies, notwithstanding all rights hereunder
      terminate on the Termination Date. If the Company willfully and knowingly fails
      to comply with any provision of this Warrant, which results in any material
      damages to the Holder, the Company shall pay to Holder such amounts as shall
      be
      sufficient to cover any costs and expenses including, but not limited to,
      reasonable attorneys’ fees, including those of appellate proceedings, incurred
      by Holder in collecting any amounts due pursuant hereto or in otherwise
      enforcing any of its rights, powers or remedies hereunder. 

    

    (d)
       Notices.
       Any
      notice, request or other document required or permitted to be given or delivered
      to the Holder by the Company shall be delivered in accordance with the notice
      provisions of the Subscription Agreement. 

    

    (e)
       Limitation
      of Liability.
       No
      provision hereof, in the absence of any affirmative action by Holder to exercise
      this Warrant or purchase Warrant Shares, and no enumeration herein of the rights
      or privileges of Holder, shall give rise to any liability of Holder for the
      purchase price of any Common Stock or as a stockholder of the Company, whether
      such liability is asserted by the Company or by creditors of the Company.

    

    (f)
       Successors
      and Assigns.
       Subject
      to applicable securities laws, this Warrant and the rights and obligations
      evidenced hereby shall inure to the benefit of and be binding upon the
      successors of the Company and the successors and permitted assigns of Holder.
      The provisions of this Warrant are intended to be for the benefit of all Holders
      from time to time of this Warrant and shall be enforceable by any such Holder
      or
      holder of Warrant Shares. 

    

    (g)
       Amendment.
       This
      Warrant may be modified or amended or the provisions hereof waived with the
      written consent of the Company and the Holder. 

    

    (h)
       Severability.
       Wherever
      possible, each provision of this Warrant shall be interpreted in such manner
      as
      to be effective and valid under applicable law, but if any provision of this
      Warrant shall be prohibited by or invalid under applicable law, such provision
      shall be ineffective to the extent of such prohibition or invalidity, without
      invalidating the remainder of such provisions or the remaining provisions of
      this Warrant. 

    

    (i)
       Headings.
       The
      headings used in this Warrant are for the convenience of reference only and
      shall not, for any purpose, be deemed a part of this Warrant. 

    

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    IN
      WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
      officer thereunto duly authorized. 

    

    

    Dated:
      ______________, 2007

     

    TASKER
      PRODUCTS CORP. 

    

    

    By:__________________________________________
      

    Name:
      Lanny R. Dacus

    Title:
      Chief Executive Officer

    
 

    
      
        
           

        

        
           

          
            

          

        

        
           

        

      

    

    

    NOTICE
      OF EXERCISE

    

    

    

    SUBSCRIPTION (cash)

    

    The
      undersigned, ___________________ (the “Holder”),
      pursuant to the provisions of the Warrant of Tasker Products, Corp. (the
“Company”)
      granted to the Holder (or its assignor) dated _____ (the “Warrant”), hereby
      agrees to subscribe for and purchase ____________________ shares of the Common
      Stock, par value $___ per share, of the Company covered by the Warrant, and
      makes payment therefor in full at the price per share provided by the
      Warrant.

    

    
      	Dated:_______________	 	Signature:_________________________

    

                   

     

    SUBSCRIPTION
      (cashless
      exercise)

    

    The
      undersigned Holder ___________________, pursuant to the provisions of the
      Warrant, hereby elects to exchange its Warrant, in whole or in part, as
      appropriate, for ______ shares of Common Stock, stated value $___ per share,
      of
      the Company, pursuant to the cashless exercise provisions of Section 3 of the
      Warrant.

    
      

      
        	Dated:_______________	 	Signature:_________________________

      

                     

    

     

    INSTRUCTIONS
      FOR REGISTRATION OF STOCK:

    

    

    
      	 	
              Name_______________________________________________

              (please
                type or print in block letters)

              

              Address______________________________________________

              

              Address______________________________________________

            	 

    

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    ASSIGNMENT
      FORM

    

    (To
      assign the foregoing warrant, execute this form and supply required information.
      Do 

    not
      use
      this form to exercise the warrant.)

    

    FOR
      VALUE
      RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
      assigned to _______________________________________________ whose address is
      _________________________________________________________. 

    

    

    
      	 	 	 	Dated: ______________, _______ 
	 	 	 	 
	 	
              Holder’s
                Signature

            	 	____________________________
	 	 	 	 
	 	 	 	 
	 	
              Holder’s
                Address:

            	 	____________________________
	 	 	 	____________________________
	 	 	 	____________________________
	 	 	 	 

    

     

    Signature
      Guaranteed: ___________________________________________ 

    

    NOTE:
      The
      signature to this Assignment Form must correspond with the name as it appears
      on
      the face of the Warrant, without alteration or enlargement or any change
      whatsoever, and must be guaranteed by a bank or trust company. Officers of
      corporations and those acting in a fiduciary or other representative capacity
      should file proper evidence of authority to assign the
      foregoingEXHIBIT
        10.36

      

      LICENSE
        AGREEMENT

      between

      CONRAD,
        Eastern Virginia Medical School

      and

      Biosyn,
        Inc., a subsidiary of Cellegy Pharmaceuticals, Inc.

       

      THIS
        AGREEMENT (this “Agreement”), effective as of the 30th day of January, 2006 by
        and between Biosyn, Inc. (“Biosyn”), a corporation organized and existing under
        the laws of the Commonwealth of Pennsylvania and a wholly owned subsidiary
        of
        Cellegy Pharmaceuticals, Inc. (“Cellegy”), and having its principal place of
        business at1800 Byberry Road, Building 13, Huntingdon Valley, PA 19006, and
        CONRAD, Eastern Virginia Medical School, (“CONRAD”), organized and existing
        under the laws of the State of Virginia and having its principal place of
        business at the address set forth in Section 10.1.

       

      WITNESSETH:

       

      WHEREAS,
        Biosyn owns or controls certain United States patents and patent applications
        and corresponding foreign patents and patent applications and related technology
        relating to compounds and formulations having microbicidal properties for
        treating or preventing the contraction of sexually transmitted diseases and/or
        inactivating pathogenic microbes;

       

      WHEREAS,
        Biosyn wishes to grant to CONRAD a non-exclusive license to its Technology
        related to such compounds and formulations (as specifically defined herein)
        in
        the Developing Countries to make, have made, use, research, develop, market
        and
        sell, but only for the Public Sector; and

       

      WHEREAS,
        CONRAD wishes to conduct research and development activities with regard
        to
        Biosyn’s Technology and to make, have made, use, research, develop, market and
        sell, in and for the benefit of the Developing Countries and for the Public
        Sector, products that incorporate the Technology and to share the results
        of
        such research and development activities with Biosyn.

       

      NOW,
        THEREFORE, in consideration of the mutual covenants and agreements of the
        parties contained herein, and intending to be legally bound, the parties
        agree
        as follows:

       

      
        	
                1.

              	
                Definitions

              

      

       

      “C31G”
        means compounds, compositions and processes covered under the C31G Patents
        in
        Schedule II, along with associated trademarks and know-how, sometimes referred
        to as Savvy, and for use in the prevention of transmission of sexually
        transmitted diseases including HIV and for contraception.

       

      “C31G
        Permitted Field of Use” means for the prevention of infection by HIV and other
        sexually transmitted pathogens and for contraception, by topical, but not
        systemic, administration.

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      “CV-N
        License” means the Patent License Agreements between Biosyn and the National
        Institutes of Health (“NIH”) by the Public Health Service (“PHS”) dated February
        27, 2003 and February 28, 2003, a copy of which is appended hereto as Schedule
        V.

       

      “CV-N
        Permitted Field of Use” means compositions, devices and methods for the
        prevention of infection by HIV and other sexually transmitted pathogens,
        by
        topical, but not systemic, administration, utilizing cyanovirin-N, anti-HIV
        mutants of cyanovirin-N, including glycosylation-resistant mutants of
        cyanovirin-N, and anti-HIV fragments of both, including conjugated forms
        of
        cyanovirin-N, mutants of cyanovirin-N, and anti-HIV fragments of both, to
        increase the in vivo half-life, but excluding pegylated cyanovirin-N, pegylated
        mutants of cyanovirin-N, and pegylated anti-HIV fragments of both. For the
        avoidance of doubt, such compositions shall include sustained release
        formulations; devices shall include all drug delivery systems, including
        but not
        limited to condoms, sponges, vaginal rings, suppositories, IUDs and other
        solid
        matrices; and topical administration shall include administration to mucosal
        membranes, including vaginal, anal and oral membranes.

       

      “Cyanovirin-N”
        or “CV-N” means a naturally occurring protein originally isolated from the
        cyanobacterium Nostoc
        ellipsosporum.

       

      “Developing
        Countries” means countries eligible for support from the Global Alliance for
        Vaccine Initiatives (GAVI) or successor organization, or which at the effective
        date of this Agreement are those countries with a Gross National Product
        of less
        than US $1,000 per capita per year, and at the effective date of this Agreement
        include those listed in Schedule I.

       

      “Patents”
        means any and all patent applications (including provisional patent
        applications) and any and all patents issuing therefrom together with any
        foreign equivalents, patents of addition, divisions, continuations,
        continuations-in-part, substitutions, extensions or renewals therefore or
        re-issues, registrations and re-validations, international applications under
        the Patent Cooperation Treaty, and including supplementary protection
        certificates or other governmental-granted exclusivity in the nature of a
        patent.

       

      “Products”
        means any product or product candidate that incorporates or is covered by
        the
        Technology.

       

      “Public
        Sector” means the U.S. government and/or the government of a Developing Country,
        or any nonprofit entity empowered by the U.S. government and/or the government
        of a Developing Country to act for said government in matters applicable
        to this
        Agreement, organizations within the United Nations system including the World
        Health Organization and UNICEF, and other nonprofit organizations when they
        purchase drugs or vaccines for delivery, manufacture and/or sale in the U.S.
        and
        Developing Countries.

       

      “Technology”
        means any technology, compounds, formulations, pharmaceutical compositions
        and
        methods and processes covered by a Valid Claim in Patents covering C31G,
        CV-N,
        or UC-781, including those patents and patent applications listed on
Schedule
        II,
        Schedule
        III,
        and
Schedule
        IV,
        respectively, a product incorporating C31G, CV-N, or UC-781 or the use or
        manufacture thereof, and/or other proprietary technology and know-how (including
        manufacturing process technology) related to C31G, CV-N, or UC-781 or any
        such
        Patents.

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      “UC-781”
        is a non-nucleoside reverse transcriptase inhibitor of the HIV-1 reverse
        transcriptase enzyme.

       

      “UC-781
        License” means the License Agreement between Biosyn, Inc., and Uniroyal Chemical
        Company, Inc., dated May 22, 2001, a copy of which is appended hereto as
        Schedule VI.

       

      “UC-781
        Permitted Field of Use” means use as a human topical microbicide, alone or in
        combination with other compounds, for application to the skin, mucosal and/or
        epithelial tissue as an active ingredient in formulations such as creams,
        foams,
        jellies, or other similar formulations, including contraceptive and other
        vaginal delivery devices such as sponges, intrauterine devices, diaphragms
        and
        condoms; but Permitted Field of Use does not include, and specifically
        excludes:

       

      (a) non-human
        uses;

       

      (b) human
        application for both systemic therapeutic uses and systemic post-exposure
        prophylactic uses; and

       

      (c) uses
        when
        applied to or incorporated into any surface (except for human surfaces
        consisting of skin, mucosal and/or epithelial tissue) or device (except
        contraceptive and other vaginal delivery devices as provided for above in
        this
        definition) including, but not limited to, gloves, aprons, tubing and
        filters.

       

      “Valid
        Claim” means a claim of any issued, unexpired Patent that has not been revoked
        or held unenforceable or invalid by a decision of a court or governmental
        agency
        of competent jurisdiction, from which no further appeal can be taken or with
        respect
        to
        which an appeal is not taken within the time allowed for appeal, and which
        has
        not been disclaimed, denied or admitted to be invalid or unenforceable through
        reissue, disclaimer or otherwise.

       

      
        	
                2.

              	
                License
                  Grant

              

      

       

      2.1 Biosyn
        hereby grants to CONRAD a non-exclusive license in the Developing Countries
        under the Technology to make, have made, use, conduct research, import, export,
        offer for sale, sell and have sold Products, solely for the Public Sector
        in the
        Developing Countries, and with respect to the Technology related to UC-781,
        only
        in the UC-781 Permitted Field of Use, with respect to the Technology related
        to
        CV-N, only in the CV-N Permitted Field of Use and with respect to the Technology
        related to C31G, only in the C31G Permitted Field of Use. CONRAD shall also
        have
        the right to make, have made and conduct research on Products anywhere in
        the
        world provided that CONRAD may only offer for sale, sell, and have sold such
        Products solely for the Public Sector in the Developing Countries. CONRAD
        shall
        have the right to grant sublicenses only with Biosyn’s written approval, which
        approval shall not be unreasonably withheld; except that CONRAD may, without
        Biosyn’s written approval, grant sublicenses to affiliated entities for the sole
        purpose of executing CONRAD’s charitable mission; provided, however, that any
        sublicense shall include all applicable restrictions and limitations of this
        Agreement.

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      2.2 Biosyn
        shall provide CONRAD access to its Investigational New Drug Applications
        for
        C31G and UC-781 and to such other data relating to C31G, UC-781 and CV-N
        in
        Biosyn’s possession as CONRAD shall reasonably request from time to time in
        order to facilitate research and development activities conducted by CONRAD.
        Any
        data or other information provided to CONRAD under this Agreement shall be
        subject to Section 8 and CONRAD shall only use the same for the sole purpose
        of
        conducting research and developing Products in the respective Permitted Fields
        of Use and for the purpose of providing the Products to the Public Sector
        in the
        Developing World (collectively, the “Purpose”). Disclosure of such data and
        other information can only be made to those representatives and agents who
        need
        to know in order to perform activities directed at the Purpose and to regulatory
        authorities for the purpose of seeking approval of such Products for the
        Purpose.

       

      2.3 Notwithstanding
        the provisions of this Agreement to the contrary, to the extent that the
        rights
        held by Biosyn to the Technology are subject to or limited by (i) rights
        held by
        the Public Health Service, the National Institutes of Health and the U.S.
        Government under the CV-N License, (ii) rights held by Uniroyal Chemical
        Company, Inc. under the UC-781 License, (iii) rights held by a government
        agency, (iv) rights of Philanthropic Ventures Holding Corporation (“PVHC”)
        granted or to be granted under the Letter of Reaffirmation, dated October
        7,
        2004, between Cellegy and PVHC, (v) rights granted or to be granted to the
        International Partnership for Microbicides under the Sponsored Development
        and
        Collaboration Agreement, dated as of January 1, 2003, or (vi) the rights
        of
        third party philanthropic organizations such as The Global Microbicide Project
        (“GMP”), the World Health Organization, USAID and the International Partnership
        for Microbicides, the parties understand and agree that rights to such
        intellectual property licensed to CONRAD hereunder are subject to such
        limitations. 

       

      2.4 As
        consideration for the licenses and rights granted to CONRAD under this
        Agreement, CONRAD shall pay a license grant fee of one hundred dollars
        ($100.00). CONRAD shall pay the license grant fee within thirty (30) days
        from
        the date of execution of this Agreement by both Parties.

      

      
        	
                3.

              	
                Term
                  and Termination

              

      

       

      3.1 This
        Agreement shall commence effective as of the date first above set forth and,
        unless earlier terminated pursuant to the terms of this Agreement, shall
        remain
        in effect until the expiration of the last-to-expire Valid Claim of Patents
        included in the Technology.

       

      3.2 CONRAD
        may terminate this Agreement at any time and for any reason or no reason
        upon
        sixty (60) days prior written notice. This Agreement may be terminated prior
        to
        expiration of the term hereof by either party in the event of any material
        breach of this Agreement by the other party that shall go uncorrected for
        a
        period of sixty (60) days after notice of such breach, setting forth the
        details
        thereof with reasonable particularity, has been given to the other party.
        In the
        event of any termination under this Section 3.2, the License shall immediately
        and automatically revert back to Biosyn.

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      
        	4.	
                Representations,
                  Warranties and Covenants

              

      

       

      4.1 Biosyn
        represents and warrants to CONRAD that (a) Biosyn is a wholly owned subsidiary
        of Cellegy Pharmaceuticals, Inc., has been duly incorporated and is a validly
        subsisting under the laws of the Commonwealth of Pennsylvania; (b) Biosyn
        has
        taken all actions necessary to authorize it to enter into and perform its
        obligations under this Agreement and to consummate the transactions contemplated
        hereby; and (c) this Agreement is a legal, valid and binding obligation of
        Biosyn, enforceable in accordance with its terms subject, as to enforcement,
        to
        bankruptcy, insolvency, reorganization and other laws of general applicability
        relating to creditors’ rights and to general equitable principles.

       

      4.2 CONRAD
        represents and warrants to Biosyn that (a) CONRAD has all requisite power
        and
        authority to enter into and perform all of its obligations under this Agreement
        and to carry out the transactions contemplated hereby in accordance with
        the
        terms and conditions set forth herein; and (b) this Agreement is a legal
        valid
        and binding obligation of CONRAD, enforceable in accordance with its terms
        subject, as to enforcement, to bankruptcy, insolvency, reorganization and
        other
        laws of general applicability relating to creditors’ rights and to general
        equitable principles.

       

      4.3 CONRAD
        covenants as follows:

       

      (a) CONRAD
        shall use commercially reasonable efforts to conduct research and/or development
        activities on Products.

       

      (b) CONRAD
        shall own all results and data CONRAD creates, develops or collects in its
        research and development activities related to Products. CONRAD hereby grants
        to
        Biosyn an option to purchase some or all such results and data as Biosyn
        elects,
        on terms that are no less favorable to Biosyn than commercially reasonable
        terms
        for such results and data, and shall negotiate in good faith the terms of
        such
        purchase with Biosyn, its parent corporation, successor or permitted assignee,
        with such terms taking into consideration, among other factors, all of the
        benefits and burdens of CONRAD hereunder and relating to the results or data
        sought to be acquired and amounts expended by Biosyn before and after the
        date
        of this Agreement related to research and development activities concerning
        the
        Technology to which the results or data relate. In all events, the amount
        payable by Biosyn (or its parent, successor or permitted assignee) shall
        not
        exceed the amount of funds expended after the date of this Agreement by CONRAD
        (excluding overhead) that are directly related to the study or trial producing
        the results and data that Biosyn desires to acquire; and the foregoing is
        intended to represent a maximum limit on payment rather than an indicia of
        a
        commercially reasonable amount. Except for sale to Biosyn as provided above,
        CONRAD shall not sell, license or otherwise provide such results or data
        to a
        third party for use other than in the Public Sector in Developing
        Countries.

       

      (c) 
        CONRAD
        hereby grants to Biosyn an option to purchase all such results and data and
        will
        discuss the terms of such purchase with Biosyn, its parent corporation,
        successor or permitted assignee in good faith, taking into consideration
        all of
        the benefits and burdens hereunder.

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      (d) CONRAD
        shall keep Biosyn informed of (i) its research and/or development activities,
        (ii) efforts to obtain regulatory approvals with respect to any Products
        it
        develops and the status of such efforts, and (iii) plans and achievements
        relating to the sale or distribution of any such Products throughout the
        Developing Countries. The parties shall meet at times and places mutually
        agreeable or shall participate in telephone conferences from time to time
        to
        enable CONRAD to report to Biosyn on the foregoing matters. Such reporting,
        whether by telephone or in meetings, shall take place not less frequently
        than
        semiannually.

       

      
        	
                5.

              	
                Limitation
                  of Liability

              

      

       

      5.1 Biosyn
        makes no representations or warranties other than those specified in Section
        4.1. Without limiting the generality of the foregoing, Biosyn makes no
        representation or warranty that any Patents are validly issued, that patent
        applications will issue, that the Technology does not infringe on any third
        party’s technology or patents, nor that persons other than Biosyn do not own or
        control technology and know-how substantially similar to technology and know-how
        comprising part of the Technology.

       

      5.2 Biosyn
        shall not have any liability for damages, whether direct, indirect, special
        or
        consequential, including without limitation damages for economic loss, death
        or
        injury to persons or damage to property, in respect of any Patent, the
        Technology or any Product, whether or not Biosyn shall be advised, shall
        have
        reason to know or in fact shall know of the possibility of such damages,
        except
        that Biosyn shall have liability for damages arising out of Biosyn’s gross
        negligence and/or willful misconduct.

       

      5.3 BIOSYN
        MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR
        A
        PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE TECHNOLOGY OR ANY
        TANGIBLE MATERIALS RELATED THERETO.

       

      5.4 Biosyn
        has no obligation to prosecute or maintain the C31G Patents, the CV-N Patents
        or
        the UC-781 Patents. Biosyn shall keep CONRAD reasonably informed of the status
        of such Patents and patent applications. In
        the
        event that Biosyn, and any successors, licensors, collaborative partners,
        licensees, or other parties, that have or are granted the right to prosecute
        such Patents elect not to proceed with the filing of any of such Patents
        or to
        cease prosecution or maintenance of any of such Patents, Biosyn shall promptly
        so advise CONRAD who may, but is not obligated to, assume responsibility
        for
        such filing, prosecution or maintenance of any such Patents at CONRAD’s own
        expense, to the extent Biosyn has the power or authority to grant such right
        to
        CONRAD under the CV-N License and UC-781 License, as applicable. Biosyn shall
        promptly assign to CONRAD Biosyn’s entire right, title and interest in and to
        any such Patents as to which CONRAD assumes responsibility under this Section
        5
        to the extent that Biosyn has any such right, title and interest.
        Notwithstanding the foregoing, any rights that might be granted to CONRAD
        under
        this Section 5.4 are limited by those rights described in Section
        2.3.

       

      5.5 The
        selection of the Technology for the development, making, use, testing,
        distribution or sale of Products is solely CONRAD’s, and Biosyn does not assume
        any responsibility whatsoever for such development, making, use, testing,
        distribution, or sale. 

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      
        	6.	
                Indemnification

              

      

       

      6.1 CONRAD
        shall indemnify and hold harmless Biosyn and its parent, subsidiaries,
        affiliates, directors, officers, employees and agents from and against any
        and
        all loss, cost, claim, damage, liability or expense (including reasonable
        attorneys’ fees, costs of suit and costs of appeal) incurred by any of them
        arising out of or in connection with any claim, action, suit, proceeding
        or
        investigation ("Claim") filed or threatened including, without limitation,
        any
        Claim alleging death or injury to any person, with respect to (a) the
        production, manufacture, testing, sale, marketing, distribution, shipment,
        transportation, handling, cleanup, use or disposal of any Product developed,
        manufactured, tested, distributed or sold by or on behalf of CONRAD, and
        (b) the
        negligence or willful misconduct of CONRAD and/or its subsidiaries, affiliates,
        directors, officers, agents, contract manufacturers, distributors, sublicensees
        and other representatives, except when such Claim arises out of Biosyn’s gross
        negligence or willful misconduct.

       

      
        	
                7.

              	
                Compliance
                  with Law

              

      

       

      7.1 CONRAD,
        its subsidiaries, affiliates, directors and officers shall, and CONRAD shall
        use
        commercially reasonable efforts to cause its agents, contract manufacturers,
        distributors, permitted sublicensees and other representatives to, comply
        with
        all United States federal, state and local laws, rules and regulations and
        all
        foreign laws, rules and regulations applicable to the development, testing,
        production, transportation, packaging, labeling, export, import, marketing,
        distribution, sale and use of any Products.

       

      
        	
                8.

              	
                Confidentiality

              

      

       

      8.1 Except
        as
        provided in Section 4.3(b), the recipient of information supplied pursuant
        to
        this Agreement shall treat the same as confidential. For purposes of this
        Section 8.1, the terms "recipient" and "recipient party" shall mean the party
        receiving information pursuant to this Agreement, its officers, directors,
        employees and agents. The foregoing obligations as to confidentiality shall
        not
        extend to any transmitted information that is publicly available at the date
        of
        its disclosure to the recipient party or which is, at that date, already
        properly in the possession of the recipient party (evidenced by writing)
        or
        which may thereafter become publicly available from sources other than the
        recipient party and its employees or which may properly thereafter become
        available to the recipient party on a non-confidential basis from a source
        other
        than the disclosing party and that is not known by the recipient party to
        be
        under an obligation of confidentiality to the disclosing party with respect
        thereto. The obligations set forth in this Section 8 shall survive for a
        period
        of five years after the expiration or termination of this
        Agreement.

       

      8.2 If
        either
        party becomes or believes that it will become legally compelled to disclose
        any
        confidential information of the other party, the party subject to such
        disclosure requirement shall give prompt written notice of such requirement
        to
        the other party prior to any such disclosure so that such other party may
        seek a
        protective order or other appropriate remedy and/or waive compliance with
        the
        provisions of Section 8.1 of this Agreement. The party subject to such
        disclosure requirement shall disclose only the portion of the confidential
        information that, in the reasonable judgment of its counsel, it is legally
        required to disclose and shall use

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      reasonable
        efforts to obtain an appropriate protective order or other reasonable assurance
        that the confidential information being disclosed will be given confidential
        treatment.

       

      
        	
                9.

              	
                Publication

              

      

       

      9.1 CONRAD
        may publish manuscripts, abstracts or the like related to its research and
        development efforts of the Products provided confidential information of
        Biosyn
        is not included, or if confidential information of Biosyn is included, after
        first obtaining approval from Biosyn to include such confidential information.
        Prior to any publication related to the Technology or the Products, CONRAD
        shall
        provide a copy of the proposed manuscript, abstract or other to Biosyn and
        allow
        Biosyn a period of thirty (30) days to identify any confidential information
        of
        Biosyn contained therein. Upon written request by Biosyn prior to expiration
        of
        the thirty (30) day period, CONRAD shall redact such confidential information
        from the proposed publication. In the event that Biosyn identifies material
        of a
        patentable nature in the proposed publication, the submission of the publication
        will be delayed for thirty (30) days in order to allow a patent application
        to
        be filed. Notwithstanding the foregoing, CONRAD may publish any information
        required of it by any law or regulation governing the manufacture, marketing,
        sale or distribution of Products.

       

      
        	
                10.

              	
                Notice

              

      

       

      10.1 All
        notices, requests, demands and other communications which are required or
        permitted to be given under this Agreement shall be in writing and shall
        be
        deemed to be duly given upon the delivery or mailing thereof, as the case
        may
        be, if hand delivered or sent by registered or certified mail, return receipt
        requested, postage prepaid, or upon delivery to an express courier service,
        addressed in any such case:

       

      if
        to
        Biosyn:

       

      Biosyn,
        Inc.

      1800
        Byberry Road, Building 13

      Huntingdon
        Valley, PA 19006

      Attn:
        President

      

      if
        to
        CONRAD:

       

      CONRAD,
        Eastern Virginia
        Medical
        School 

      1611
        North Kent Street

      Suite
        806

      Arlington,
        VA 22209

      Attn:
        Henry L. Gabelnick, Ph.D., Executive Director

      

      or
        to
        such other address as either party shall have specified for itself by notice
        to
        the other given in accordance with this Section 10.1.

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      
        	11.	
                Use
                  of Name

              

      

       

      11.1 Except
        as
        otherwise provided herein, neither party shall have any right, express or
        implied, to use in any manner the name of the other party or any other trade
        name or trademark or other identifying mark or symbol of the other party
        for any
        purpose in connection with the performance of this Agreement.

       

      
        	
                12.

              	
                Assignment;
                  Successors

              

      

       

      12.1 Assignment.
        Neither
        Biosyn nor CONRAD may assign this Agreement without the prior written consent
        of
        the other party, except that (a) Biosyn may assign this Agreement in whole
        or in
        part to an affiliated entity, to a successor, or to the purchaser of the
        related
        assets and (b) CONRAD may assign this Agreement to affiliated entities for
        the
        sole purpose of executing CONRAD’s charitable mission; provided in each case
        that the assigning party provides prior written notice thereof to the
        non-assigning party confirming that the assignee has agreed in writing to
        be
        bound by the terms hereof.

       

      12.2 Binding
        Upon Successors and Assigns.
        Subject
        to the limitations on assignment herein, this Agreement shall be binding
        upon
        and inure to the benefit of any successors in interest and assigns of Biosyn
        and
        CONRAD. Any such successor or assignee of either party’s interest shall
        expressly assume in writing the performance of all the terms and conditions
        of
        this Agreement to be performed by such party.

       

      
        	
                13.

              	
                Applicable
                  Law

              

      

       

      13.1 This
        Agreement shall be construed in accordance with the laws of the Commonwealth
        of
        Virginia without giving effect to any conflict of law principles.

       

      
        	
                14.

              	
                Announcements

              

      

       

      14.1 All
        press
        releases and other public announcements related to the subject matter hereof
        shall be made only with the mutual written agreement of the parties hereto
        (which shall not be unreasonably withheld or delayed), except that any such
        public announcement required by law (including regulations of the FDA or
        Securities and Exchange Commission) may be made without such written
        agreement.

       

      
        	
                15.

              	
                General

              

      

       

      15.1 This
        Agreement shall be binding upon and inure to the benefit of the parties hereto
        and their respective successors.

       

      15.2 This
        Agreement sets forth and constitutes the entire agreement between the parties
        hereto with respect to the subject matter hereof, and supersedes any and
        all
        prior agreements, understandings, promises and representations made by either
        party to the other concerning the subject matter hereof and the terms applicable
        hereto. No other terms and conditions shall be binding on either party including
        terms that may be additional to or at variance with the terms hereof, unless
        such provision is expressly agreed to in writing signed by both parties
        hereto.

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      15.3 If
        any
        provision of this Agreement is or becomes or is deemed invalid, illegal or
        unenforceable in any jurisdiction to which the Agreement is sought to be
        enforced, (a) such provision shall be deemed amended to conform to applicable
        laws of such jurisdiction so as to be valid and enforceable or, if it cannot
        be
        so amended without materially altering the intention of the parties, it shall
        be
        stricken; (b) the validity, legality and enforceability of such provision
        shall
        not in any way be affected or impaired thereby in any other jurisdiction;
        and
        (c) the remainder of this Agreement shall remain in full force and
        effect.

       

      15.4 Dispute
        Resolution.
        All
        disputes arising in connection with this Agreement which cannot be settled
        in an
        amicable way between CONRAD or EVMS and Biosyn within sixty (60) days shall
        be
        mediated in good faith. The Party raising such dispute shall promptly advise
        the
        other Party of such claim, dispute or controversy in a writing which describes
        in reasonable detail the nature of such dispute. By not later than fifteen
        (15)
        business days after the recipient has received such notice of dispute, each
        Party shall have selected for itself a representative who shall have the
        authority to bind such Party, and shall additionally have advised the other
        Party in writing of the name and title of such representative. By not later
        than
        fifteen (15) business days after the date of such notice of dispute, the
        Party
        against whom the dispute shall be raised shall select a mediation firm in
        Richmond, Virginia, if it is initiated by Biosyn and in Huntingdon Valley,
        Pennsylvania if it is initiated by CONRAD or EVMS. Such representatives shall
        schedule a date with such firm for a mediation hearing. The Parties shall
        enter
        into a good faith mediation. The mediation shall be non-binding and shall
        constitute a binding and final resolution upon mutual agreement of the parties.
        The prevailing Party shall be entitled to an award of reasonable attorney
        fees
        incurred in connection with the mediation in such amount as may be determined
        by
        the mediators. 

       

      15.5 Sovereign
        Immunity.
        Nothing
        in this Agreement shall be construed to waive the sovereign immunity of Eastern
        Virginia Medical School.

       

      15.6 Force
        Majeure.
        Neither
        Party will be liable for any failure or delay in its performance under this
        Agreement due to any cause beyond its reasonable control, including acts
        of war,
        acts of God, earthquake, flood, fire, embargo, riot, sabotage, labor shortage
        or
        dispute, governmental act, or failure of third party power or telecommunications
        networks, provided that the delayed Party: (a) gives the other Party prompt
        notice of such cause, and (b) uses its reasonable commercial efforts to promptly
        correct such failure or delay in performance. Notwithstanding the foregoing,
        if
        such event causes a delay in performance of more than ninety (90) days, the
        unaffected Party shall have the right to terminate this Agreement without
        penalty upon written notice at any time prior to the affected Party’s resumption
        of performance.

       

      [signature
        page to follow]

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      IN
        WITNESS WHEREOF, the parties hereto have caused this License Agreement to
        be
        executed by their respective authorized representatives on the dates indicated
        below.

       

      

       

      BIOSYN,
        INC.

       

      Date:
        January 31, 2006

      By:
         /s/
        Anne-Marie Corner 
        
          

        

      

      Name:
        Anne-Marie Corner

      Title:
        Senior Vice President

       

       

      CONRAD

      Eastern
        Virginia Medical School

      Date:
        January 31, 2006

       

      By:
         /s/
        Henry
        L. Gabelnick 
        
          

        

      

      Name:
        Henry L. Gabelnick, Ph.D.

      Title:
        Executive Director

       

      Eastern
        Virginia Medical School

      Date:
        January 31, 2006

      By:
         /s/
        Mark
        Babashanian 
        
          

        

      

      Name:
        Mark Babashanian

      Title:
        Vice President of Administration & Finance

      

       

      Acknowledged
        and Agreed to:

       

      CELLEGY
        PHARMACEUTICALS, INC.,

      parent
        corporation to Biosyn, Inc.

       

      

      Date:
        January 31, 2006

       

      By: 
        /s/
        Richard C. Williams 
        
          

        

      

      Name:Richard
        C. Williams

      Title:
        Chairman/Interim CEO

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      SCHEDULE
        I

       

      Initial
        List of Developing Countries

       

      
        	
                Afghanistan

                Albania

                Angola

                Armenia

                Azerbaijan

                Bahamas

                Belize

                Bangladesh

                Barbados

                Benin

                Bhutan

                Bolivia

                Bosnia
                  and Herzegovina

                Botswana

                Burkina
                  Faso

                Burundi

                Cambodia

                Cameroon

                Central
                  African

                Republic
                  Chad

                China

                Comoros

                Congo

                Dominican
                  Republic

                Republic
                  oldie Congo

                Cote
                  d'Ivoirc

                Cuba

                Djibouti

                Eritrea

                Ethiopia

                Gambia

                Georgia

                Ghana

                Guinea

                Guinea
                  Bissau

                Guatemala

                Guyana

                Haiti

                Honduras

                India

                Indonesia

                Kenya

                Korea
                  DPR

                Kyrgyz
                  Republic

              	
                Lao
                  PDR

                Lesotho

                Liberia
                  

                Madagascar

                Malawi

                Mali

                Mauritania

                Moldova

                Mongolia

                Mozambique

                Myanamar

                Namibia

                Nepal

                Nicaragua

                Niger

                Nigeria

                Pakistan

                Panama

                Papua
                  New Guinea

                Rwanda

                Sao

                Tome

                Senegal
                  Sierra

                Leone

                Solomon
                  Islands

                Somalia
                  

                South
                  Africa

                Sri
                  Lanka

                Sudan

                Suriname

                Swaziland

                Thailand

                Tajikistan

                Tanzania

                Togo

                Trinidad

                Tobago

                Turkmenistan

                Ukraine

                Uganda

                Uzbekistan

                Vietnam

                Yemen

                Zambia

                Zimbabwe

                 

              

      

      

      
        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      SCHEDULE
        II

      C3IG
        Patent Listing

       

      
        	I)	
                U.S.
                  Filings

              

      

       

      
        	
                Parent
                  Number

              	
                Inventor

              	
                Date
                  Issued

              	
                Title

              
	
                4,839,158

              	
                Edwin
                  B. Michaels

              	
                6/13/89

              	
                Process
                  and composition for oral hygiene

              
	
                5,314,917

              	
                Michaels
                  and Malamud

              	
                5/24/94

              	
                Method
                  for Inactivating Enveloped Viruses and Sperm

              
	
                6,297,278

              	
                Michaels
                  and Malamud

              	
                10/2/01

              	
                Method
                  for Inactivating Sexually Transmitted. Enveloped Viruses

              
	
                5,389,676

              	
                Edwin
                  B. Michaels

              	
                2/14/95

              	
                Viscous
                  Surfactant Emulsion Compositions

              
	
                5.275,804

              	
                Edwin
                  B. Michaels

              	
                1⁄4
                  /194

              	
                Process
                  and Composition for Oral Hygiene

              
	
                5,403,579

              	
                Edwin
                  B. Michaels

              	
                4/4/95

              	
                Process
                  and Composition for Oral Hygiene

              
	
                5.244,652

              	
                Edwin
                  B. Michaels

              	
                9/14/93

              	
                Viscous
                  Surface Active Composition

              
	
                6,281,176* }

              	
                R.S.
                  Cochran 8/28/0I

              	
                8/28/01

              	
                Process
                  for producing betainc/amine oxide
                  mixtures

              

      

       

      
        	
              	•	
                This
                  patent is held by Albemarle Corp. and protects the single process
                  production method for C31G. Biosyn has an exclusive license option
                  for
                  this protected process.

              

      

       

      
        	ii)	
                International
                  Filings

              

      

       

      Equivalents
        for USPN
        4,839,158; 5,275,804; 5,403,579

       

      
        	
                Patent
                  Number

              	
                Country

              	
                Issued

              	
                Status

              
	
                606861

              	
                Australia

              	
                7/9/1991

              	
                Issued

              
	
                1315693
                  

              	
                Canada

              	
                4/6/1993

              	
                Issued

              
	
                EP0294391

              	
                Switzerland

              	
                2/2/1994

              	
                Issued

              
	
                3789020.4

              	
                Germany

              	
                2/2/1994

              	
                Issued

              
	
                EP0294391

              	
                France

              	
                2/2/1994

              	
                Issued

              
	
                EP0294391

              	
                United
                  Kingdom

              	
                2/2/1994

              	
                Issued

              
	
                2/2/1994

              	
                Issued

              
	
                EP0294391

              	
                Italy

              
	
                2548265

              	
                Japan

              	
                8/8/1996

              	
                Issued

              
	
                EP0294391

              	
                Netherlands

              	
                2/2/1994

              	
                Issued

              
	
                EP0294391

              	
                Sweden

              	
                2/2/1994

              	
                Issued

              

      

      

      
        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      [X]
        Designates portions of this document that have been omitted pursuant to a
        request for confidential treatment filed separately with this
        commission.

       

      Equivalents
        for USPN 5,244,652

      

      
        	
                Patent
                  Number

              	
                Country
                  

              	
                Issued

              	
                Status

              
	
                663506

              	
                Australia

              	
                2/6/1996

              	
                Issued

              
	
                [X]

              	
                [X]

              	
                [X]

              	
                [X]

              
	
                EP0576585

              	
                Switzerland

              	
                12/20/1995

              	
                Issued

              
	
                69206976.6

              	
                Germany
                  

              	
                12/20/1995

              	
                Issued

              
	
                EP0576585

              	
                France

              	
                12/20/1995

              	
                Issued

              
	
                EP0576585

              	
                United
                  Kingdom

              	
                12/20/1995

              	
                Issued

              
	
                EP0576585

              	
                Italy

              	
                12/20/1995

              	
                Issued
                  

              
	
                [X]

              	
                [X]

              	
                [X]

              	
                [X]

              
	
                202057

              	
                South
                  Korea

              	
                3/17/1999

              	
                Issued

              
	
                EP0576585

              	
                Netherlands

              	
                12/20/1995

              	
                Issued

              
	
                6991/94

              	
                South
                  Africa

              	
                6/28/1995

              	
                Issued

              

      

       

      Equivalents
        for USPN 5,314,917; 6,297,278

       

      
        	
                Patent
                  Number

              	
                Country
                  

              	
                Issued

              	
                Status

              
	
                AP327

              	
                Aripo

              	
                3/21/1994

              	
                Issued

              
	
                661968

              	
                Australia
                  

              	
                12/12/1995

              	
                Issued

              
	
                2106683

              	
                Canada

              	
                9/24/2002

              	
                Issued

              
	
                E0733361

              	
                Switzerland

              	
                5/30/2001

              	
                Issued

              
	
                E0576425

              	
                Switzerland

              	
                2/3/1999

              	
                Issued

              
	
                69130871

              	
                Germany

              	
                2/3/1999

              	
                Issued

              
	
                69132621.2

              	
                Germany

              	
                5/30/2001

              	
                Issued

              
	
                EP0576425

              	
                France

              	
                2/3/1999

              	
                Issued

              
	
                EP0733361

              	
                France

              	
                5/30/2001

              	
                Issued

              
	
                EP0576425

              	
                United
                  Kingdom

              	
                2/3/1999

              	
                Issued

              
	
                EP0733361

              	
                United
                  Kingdom

              	
                5/30/2001

              	
                Issued

              
	
                EP0576425

              	
                Italy

              	
                2/3/1999

              	
                Issued

              
	
                EP0733361

              	
                Italy

              	
                5/30/2001

              	
                Issued

              
	
                [X]

              	
                [X]

              	
                [X]

              	
                [X]

              
	
                3228928

              	
                Japan

              	
                9/7/2001

              	
                Issued

              
	
                227773

              	
                South
                  Korea

              	
                8/5/1999

              	
                Issued

              
	
                221486

              	
                South
                  Korea

              	
                6/28/1999

              	
                Issued

              
	
                92/0017

              	
                Namibia

              	
                11/25/1992

              	
                Issued

              
	
                EP0576425

              	
                Netherlands

              	
                2/3/1999

              	
                Issued

              
	
                EP0733361

              	
                Netherlands

              	
                5/30/2001

              	
                Issued

              
	
                9911

              	
                African
                  Union

              	
                9/15/1994

              	
                Issued

              
	
                2110256

              	
                Russian
                  Fed.

              	
                7/17/1991

              	
                Issued

              
	
                EP0733361

              	
                Sweden

              	
                5/30/2001

              	
                Issued

              
	
                EP0576425

              	
                Sweden

              	
                2/3/1999

              	
                Issued

              
	
                92/1981

              	
                South
                  Africa

              	
                11/25/1992

              	
                Issued

              

      

       

      Equivalents
        for USPN 5,389,676

       

      
        	
                Patent
                  Number

              	
                Country '
                  Issued

              	
                Status

              
	
                685507

              	
                Australia

              	
                9/9/1997

              	
                Issued

              
	
                2171294

              	
                Canada

              	
                9/9/1994

              	
                Issued

              
	
                EP0719137

              	
                Switzerland

              	
                2/20/2002

                2/20/2002

              	
                Issued

              
	
                69429922.7

              	
                Germany

              	
                2/20/2002

              	
                Issued

              
	
                EP0719137

              	
                European
                  Patent

              	
                2/20/2002

              	
                Issued

              
	
                EP0719137

              	
                Spain

              	
                2/20/2002

              	
                Issued

              
	
                EP0719137

              	
                France

              	
                2/20/2002

              	
                Issued

              
	
                EP07137

              	
                United
                  Kingdom

              	
                2/20/2002

              	
                Issued

              
	
                EP071937

              
	
                Italy

              	
                2/20/2002

              	
                Issued

              
	
                509240/95

              	
                Japan

              	
                9/9/1994

              	 
	
                178857

              	
                South
                  Korea

              	
                11/25/1998

              	
                Issued

              
	
                184513

              	
                Mexico

              	
                4/23/1997

              	
                Issued

              
	
                MY-112403-

              	
                Malaysia

              	
                6/30/2401

              	
                Issued

              
	
                EP0719137

              	
                Netherlands

              	
                2/20/2002
                  

              	
                Issued

              
	
                EP0719137

              	
                Sweden

              	
                2/20/2002

              	
                Issued

              

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      SCHEDULE
        III

       

      CV-N
        Patent Listing

       

      
        	i)	
                U.S.
                  Filings

              

      

       

      
        	Patent
                Number	
                Inventor

              	
                Date
                  Issued

              	
                Title

              
	
                5,843,882

                 

              	
                Boyd,
                  et al.

                 

              	
                12/1/98

                 

              	
                Antiviral
                  Proteins and Peptides, DNA, DNA-

                coding
                  Sequences Thereof, and Uses thereof

              
	
                5,821,081

              	
                Boyd,
                  et al.

              	
                10/13/98

              	
                Nucleic
                  Acids Encoding Antiviral Proteins and

                Peptides,
                  Vectors and Host Cells Comprising

                Same,
                  and Methods of Producing the Antiviral Proteins and
                  Peptides

              
	
                5,962,653

              	
                Boyd,
                  et a].

              	
                10/5/99

              	
                Methods
                  of Obtaining Antiviral Proteins and Antiviral Peptides from Nostoc
                  Ellipsosporum

              
	
                5,962,668

                 

              	
                Boyd,
                  et al.

              	
                10/5/99

              	
                 Nucleic
                  Acids Encoding Antiviral

                Proteins
                  and Peptides Fused to

                Effector
                  Proteins

              
	
                6,015,876

                 

              	
                Michael
                  R.

                Boyd

              	
                1/18/00

                 

              	
                Method
                  of Using Cyanovirins

                 

              
	
                5,998,587

              	
                Boyd,
                  et al,

              	
                12/7/.99

              	
                Anti-cyanovirin
                  Antibody

              
	
                6,245,737

              	
                Michael
                  R.

              	
                6/12/01

              	
                Conjugates
                  of antiviral proteins or peptides and

              
	 	
                Boyd

                ___.-_.

              	 	
                virus rviral-envelope
                  glycoproteins

              
	
                6,420,
                  336 B1

              	
                Michael
                  R.

              	
                7/16/02

              	
                Methods
                  of Using Cyanovirins Topically to

              
	 	
                Boyd

              	 	
                Inhibit
                  Viral Infection

              
	
                6,428,790
                  B1

              	
                Michael
                  R.

              	
                8/6/02

              	
                 Cyanovirin
                  Conjugates and Matrix-Anchored

              
	 	
                Boyd

                 

              	 	
                Cyanovirin
                  and Related Compositions and

                Methods
                  of Use

              
	
                U.S.
                  Patent Appl.

              	
                Michael
                  R.

              	
                10/27/99

              	
                Methods
                  of Using Cyanovirins to Inhibit Viral

              
	
                No.

              	
                Boyd

              	 	
                Infection

              
	
                09/427,873

              	 	 	 
	
                U.S.
                  Patent Appl

                No.

                09/815,079

              	
                Michael
                  R. Boyd

              	
                03/22/01

              	
                Glycosylation-Resistant
                  Cyanovirins and Related Conjugates, Compositions, Nucleic Acids,
                  Vectors,
                  Host Cells, Methods of Production and Methods of Using Nonglycosylated
                  Cyanovirins

              
	
                U.S_
                  Patent Appl.

              	Michael
                R. 	9/12/01	
                Cyanovirin
                  Conjugates and Matrix-Anchored

              
	
                No.
                  09/951,189

              	Boyd	   	
                Cyanovirin
                  and Related Compositions and

                Methods
                  of Use

              

      

       

      Other
        Biosyn Patents Pending 

      

      
        	
                [X]

              	
                [X]

              	
                [X]

              	
                [X]

              

      

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

        [X]
          Designates portions of this document that have been omitted pursuant to
          a
          request for confidential treatment filed separately with this
          commission.

         

      

      Schedule
        IV

       

      UC-781
        Patent Listing

      

      
        	i)	
                U.S.
                  Filings

              

      

      

      
        	
                Patent
                  Number

              	
                Inventor

              	
                Date
                  Issued

              	
                Title

              
	
                5,268,389

              	
                Harrison,
                  et al.

              	
                12/7/93

              	
                Thiocarboxylate
                  ester compositions containing the same

              
	
                5,693,827

              	
                Harrison,
                  et al.

              	
                12/2/97

              	
                Treatment
                  of HIV infections and compounds useful therein

              
	
                5,696,151

              	
                Brouwer,
                  et al.

              	
                12/9/97

              	
                Compounds
                  useful for the inhibition of the replication of HIV-1 and HIV-1
                  mutants

              
	
                6,017,947

              	
                Brouwer,
                  et al.

              	
                1/25/00

              	
                Heterocyclic
                  carbodithioperoxyimidic compounds useful for the inhibition of
                  the
                  replication of HIV

              
	
                PCT

                WO
                  97/45116

              	
                Borkow
                  et al.

              	
                5/23/97

              	
                Use
                  of Thiocarboxanilide derivatives for the preparation of a medicament
                  for
                  preventing the transmission of HIV to uninfected cells and contraceptive
                  compositions comprising the said
                  derivatives

              

      

      

      
        	ii)	
                International
                  Filings

              

      

      

      
        	 	
                o

              	
                Filings
                  equivalent to USPNs 5,268,389 and
                  5,693,827

              

      

      

      
        	
                Patent
                  Number

              	
                Country

              	
                Application
                  Number

              
	
                0497816

              	
                Austria

              	
                90915588.9

              
	
                616409

              	
                Australia

              	
                66035/90

              
	
                0497816

              	
                Belgium

              	
                90915588.9

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                0497816

              	
                Switzerland

              	
                90915588.9

              
	
                69019533.8

              	
                Germany

              	
                90915588.9

              
	
                0497816

              	
                Denmark

              	
                90915588.9

              
	
                0497816

              	
                France

              	
                90915588.9

              
	
                0497816

              	
                Great
                  Britain

              	
                90915588.9

              
	
                3017128

              	
                Greece

              	
                90915588.9

              
	
                198/5

              	
                Haiti

              	 
	
                Published
                  

              	
                Hungary

              	
                P9201258

              
	
                95956

              	
                Israel

              	
                95956

              
	
                0497816

              	
                Italy

              	
                90915588.9

              
	
                1967760

              	
                Japan

              	
                514569/90

              
	
                0222233

              	
                South
                  Korea

              	
                700831/92

              
	
                0497816

              	
                Luxembourg

              	
                90915588.9

              
	
                179450

              	
                Mexico

              	
                22844

              
	
                920R.P.I

              	
                Nicaragua

              	
                91-009

              
	
                0497816

              	
                Netherlands

              	
                90915588.9

              
	
                235653

              	
                New
                  Zealand

              	
                235653

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                2108785

              	
                Russian
                  Fed.

              	
                5011885.04

              
	
                0497816

              	
                Sweden

              	
                90915588.9

              
	
                NI-58187

              	
                Taiwan

              	
                79108696

              
	
                90/8094

              	
                South
                  Africa

              	
                90/8094

              

      

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      
        	
              	o	
                Filings
                  equivalent to USPN 5,696,151

              

      

      

      
        	
                Patent
                  Number

              	
                Country

              	
                Application
                  Number

              
	
                AP902

              	
                Kenya

              	
                AP/P/98/01245

              
	
                AP902

              	
                Gambia

              	
                AP/P/98/01245

              
	
                AP902

              	
                Ghana

              	
                AP/P/98/01245

              
	
                AP902

              	
                Africa
                  (ARIPO)

              	
                AP/P/98/01245

              
	
                AP902
                  

              	
                Lesotho

              	
                AP/P/98/01245

              
	
                AP902

              	
                Malawi

              	
                AP/P/98/01245

              
	
                AP902

              	
                Sudan

              	
                AP/P/98/01245

              
	
                AP902

              	
                Swaziland

              	
                AP/P/98/01245

              
	
                AP902

              	
                Uganda

              	
                AP/P/98/01245

              
	
                704086

              	
                Australia

              	
                11199/97

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                229-REG.5

              	
                Haiti

              	 
	
                [X]

              	
                [X]

              	
                [X]

              
	
                3027771

              	
                Japan

              	
                520533/97

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                324118

              	
                New
                  Zealand

              	
                324118

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                96/9490

              	
                South
                  Africa

              	
                96/9490

              

      

       

      
        	
              	
                o

              	
                Filings
                  equivalent to PCT WO 97/45116

              

      

      

      
        	
                Patent
                  Number

              	
                Country

              	
                Application
                  Number

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              
	
                [X]

              	
                [X]

              	
                [X]

              

      

      

      

        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      SCHEDULE
        V

       

      Public
        Health Service Patent License Agreement - Exclusive, between 

      Public
        Health Service agencies and Biosyn, Inc.

      

      Incorporated
        by reference to Exhibit 10.22 to the Registrant’s Annual Report on Form 10-K for
        the year ended December 31, 2004, filed with the Commission.

      

      
        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      SCHEDULE
        VI

       

      License
        Agreement dated May 22, 2001, between 

      Biosyn,
        Inc. and Crompton Corporation.

      

      

      Incorporated
        by reference to Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K for
        the year ended December 31, 2004, filed with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]